Business
Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System
Strong interest in ProSense from healthcare providers in Canada strengthens market potentialProSense now approved throughout North AmericaCAESAREA, Israel,
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Strong interest in ProSense from healthcare providers in Canada strengthens market potentialProSense now approved throughout North AmericaCAESAREA, Israel, July 24, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (\"IceCure\" or the \"Company\"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that Health Canada, the Canadian government's regulatory agency, has approved IceCure's ProSense System, disposable cryoprobes, and introducers as cryosurgical tools for indications including:\nTumors – ablation of benign and malignant tumors of the lung, liver, kidneys, and musculoskeletal system, and benign tumors of the breast;General surgery;Palliative intervention; andOther surgeries. \n \n\"As we continue to gain traction in the United States, this approval in Canada will create synergies for us in the broader North American market. We have been directly engaging with healthcare providers through education, hands-on training seminars, marketing, and sales in the U.S. and we will expand these activities into Canada. We have already been contacted by multiple Canadian healthcare providers with requests to purchase and implement ProSense,\" stated IceCure Chief Executive Officer, Eyal Shamir.\nCanada's healthcare system is ranked as one of the top in the world, with total health spending estimated at $331 billion in 2022.\nIceCure's cryoablation system currently has regulatory approval for various indications in 15 countries, including in the U.S., Europe, and China.\nAbout IceCure Medical\nIceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.\nForward Looking Statements\nThis press release contains forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Re...